Catalent, Inc. (NYSE:CTLT) Shares Sold by North Star Asset Management Inc.

North Star Asset Management Inc. decreased its holdings in Catalent, Inc. (NYSE:CTLT) by 29.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,783 shares of the company’s stock after selling 16,467 shares during the quarter. North Star Asset Management Inc.’s holdings in Catalent were worth $2,237,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of CTLT. Nomura Holdings Inc. lifted its holdings in shares of Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after purchasing an additional 6,881,914 shares during the period. Norges Bank purchased a new stake in Catalent during the fourth quarter worth about $116,021,000. Capital World Investors grew its position in Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after buying an additional 1,098,474 shares during the period. Magnetar Financial LLC purchased a new position in Catalent in the first quarter valued at about $56,429,000. Finally, Cadian Capital Management LP increased its holdings in Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after buying an additional 759,600 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on CTLT shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. Barclays raised their target price on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. StockNews.com began coverage on shares of Catalent in a research report on Monday, September 2nd. They issued a “sell” rating on the stock. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $58.08.

Catalent Stock Down 0.6 %

Shares of NYSE:CTLT opened at $60.03 on Friday. Catalent, Inc. has a 12-month low of $31.80 and a 12-month high of $61.20. The stock’s 50-day moving average price is $58.88 and its two-hundred day moving average price is $57.07. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The firm has a market cap of $10.86 billion, a price-to-earnings ratio of -9.84, a PEG ratio of 2.52 and a beta of 1.16.

Insider Buying and Selling

In other news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at approximately $2,360,264.25. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Scott Gunther sold 666 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,409 shares of company stock valued at $782,923. Insiders own 0.31% of the company’s stock.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.